Scientific Reports (Feb 2024)

A pilot study for risk stratification of ventricular tachyarrhythmia in hypertrophic cardiomyopathy with routine echocardiography parameters

  • Anselm A. Derda,
  • Malin Abelmann,
  • Jan-Thorben Sieweke,
  • Florian J. G. Waleczek,
  • Natalie Weber,
  • Nadine Zehrfeld,
  • Christian Bär,
  • David Duncker,
  • Udo Bavendiek,
  • Dominik Berliner,
  • Johann Bauersachs,
  • Kristina Sonnenschein,
  • Thomas Thum

DOI
https://doi.org/10.1038/s41598-024-54153-2
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Ventricular tachyarrhythmia (VTA) are frequent arrhythmias in patients with hypertrophic cardiomyopathy (HCM). Representing a major risk factor for sudden cardiac death, Holter ECG at first clinical presentation appears insufficient. This study aims to investigate the ability of routinely obtained parameters associated with myocardial remodeling in stratifying for VTA in HCM. In this monocentric analysis, patients with HCM underwent 12-channel electrocardiography and echocardiography, including tissue doppler imaging. The study’s primary endpoint was the documentation of non-sustained and sustained ventricular tachycardia—summarized as ventricular tachyarrhythmias (VTA) on Holter ECG or active devices. The occurrence of VTA was exploratory. Based on our collective, we developed a risk model regarding VTA. Of 140 HCM patients, 38 (27.1%) had an episode of VTA. Patients with VTA were likelier to have a history of atrial fibrillation (p < 0.001), a thicker interventricular septum (p < 0.001) and lower peak systolic mitral annular velocity (p < 0.001). The parameters were independently associated with endpoint in univariate and multivariate logistic regression. We created a logistic equation and calculated a cut-off value. The resulting ROC curve revealed a discriminative ability with AUC of 0.80 (sensitivity, 63%; specificity, 88%). Our risk model including these widely available parameters is able to distinguish low and high-risk of VTA in patients with HCM.